Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07573943 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 20% 150 → 120 participants
See other at-risk trials from The Second Affiliated Hospital of Chongqing Medical University

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 150 → 120 participants
    • Trial arms changed: 5 → 3
    • Eligibility criteria revised
    • Collaborators shortened, about 17 words
    v3
  2. Eligibility criteria expanded, about 371 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.
Trial Details
NCT Number NCT07573943
Lead Sponsor The Second Affiliated Hospital of Chongqing Medical University
Conditions
(from sponsor)		 Chronic Hepatitis b
Related terms Hepatitis B, Chronic
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov